Michael J. Hassett, MD, MPH

Michael Hassett, MD, MPH, discusses the rise of oral therapeutics in breast cancer care, emphasizing patient support, education, and overcoming financial barriers for better outcomes.

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer Institute in Boston.

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer treatment continuum.

Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.